subscribeSubscribe
Novo Nordisk to discontinue Levemir insulin in U.S. market

Novo Nordisk to discontinue Levemir insulin in U.S. market
REUTERS
09 Nov 2023
Share Share
Novo`s Biologic Xultophy (Degludec, Liraglutide) Receives Approval in the U.S.

Novo`s Biologic Xultophy (Degludec, Liraglutide) Receives Approval in the U.S.
FDA
10 Jul 2023
Share Share
Novo`s Biologic Ryzodeg (Insulin aspart & insulin degludec ) Receives Approval in the U.S.

Novo`s Biologic Ryzodeg (Insulin aspart & insulin degludec ) Receives Approval in the U.S.
FDA
06 Oct 2022
Share Share
Novo`s insulin degludec:Liraglutide Receives Approval in the U.S.

Novo`s insulin degludec:Liraglutide Receives Approval in the U.S.
FDA
01 Jul 2022
Share Share
Once-weekly insulin icodec shows superior reduction in HbA1c vs insulin degludec

Once-weekly insulin icodec shows superior reduction in HbA1c vs insulin degludec
GLOBENEWSWIRE
28 Apr 2022
Share Share
Novo Nordisk Issues Voluntary Nationwide Recall of Levemir®

Novo Nordisk Issues Voluntary Nationwide Recall of Levemir®
FDA
11 May 2021
Share Share
Tresiba lowers risk of hypos in type II diabetes

Tresiba lowers risk of hypos in type II diabetes
Anna Smith PHARMATIMES
20 Sep 2019
Share Share
Novo`s Tresiba misses main mark in head-to-head Toujeo tilt

Novo`s Tresiba misses main mark in head-to-head Toujeo tilt
Carly Helfand FIERCE PHARMA
19 Sep 2019
Share Share
Novo faces shareholder suit over insulin sales disclosures

Novo faces shareholder suit over insulin sales disclosures
Ned Pagliarulo BIOPHARMADIVE
16 Aug 2019
Share Share
Sanofi talks up personalized diabetes care in patient-centric awareness push

Sanofi talks up personalized diabetes care in patient-centric awareness push
Beth Snyder Bulik FIERCE PHARMA
10 Jun 2019
Share Share